NextGen Stars Class of 2024 Honoree Israel Cañadas, PhD, will present an abstract on targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in small cell lung cancer during a session on Monday, April 8.

NextGen Stars Class of 2024 Honoree Gabriele Casirati, MD, PhD, will present an abstract on epitope editing enabling targeted immunotherapy of acute myeloid leukemia during a session on Monday, April 8.

NextGen Stars Class of 2024 Honoree Kathleen Houlahan, PhD, will present an abstract on germline-mediated immunoediting that sculpts breast cancer subtypes and metastatic proclivity during a session on Monday, April 8.

NextGen Stars Class of 2024 Honoree Kara N. Maxwell, MD, PhD, will present an abstract on distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers during a session on Monday, April 8.

NextGen Stars Class of 2024 Honoree Olivier Saulnier, PhD, will present an abstract on tracing the developmental origins of group 3 medulloblastoma during a session on Monday, April 8.

NextGen Stars Class of 2024 Honoree Alison M. Taylor, PhD, will present an abstract on functional and computational approaches to uncover selection advantages of cancer aneuploidy during a session on Monday, April 8.

NextGen Stars Class of 2024 Honoree Arnav Mehta, MD, PhD, will present an abstract on dissecting and quantifying pancreatic cancer plasticity using single-cell multiomics, lineage tracing and functional genomics during a session on Tuesday, April 9.

NextGen Stars Class of 2024 Honoree Claire E. Thomas, PhD, MPH, will present an abstract on the association between somatic microsatellite instability, hypermutation status, and specific T cell subsets in colorectal cancer tumors during a session on Tuesday, April 9.

NextGen Stars Class of 2024 Honoree Ignacio Vazquez-Garcia, PhD, will present an abstract on the evolutionary dynamics of whole-genome doubling in ovarian cancer during a session on Tuesday, April 9.

NextGen Stars Class of 2024 Honoree Abhijit Parolia, MS, PhD, wil present an abstract on NSD2 as a druggable subunit of the AR neo-enhanceosome in prostate cancer during a session on Wednesday, April 10.